Low Frequency of p53 Gene Mutation in Tumors Induced by Aflatoxin B<sub>1</sub> in Nonhuman Primates

Yoshinori Fujimoto, Lori L. Hampton, Lin-di Luo, Peter J. Wirth, and Snorri S. Thorgeirsson

Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892

Abstract

Aflatoxin B<sub>1</sub> has been suggested as a causative agent for a G to T mutation at codon 249 in the p53 gene in human hepatocellular carcinomas from southern Africa and Qidong in China. To test this hypothesis, nine tumors induced by aflatoxin B<sub>1</sub> in nonhuman primates were analyzed for mutations in the p53 gene. These included four hepatocellular carcinomas, two cholangiocarcinomas, a spindle cell carcinoma of the bile duct, a hemangioendothelial sarcoma of the liver, and an osteogenic sarcoma of the tibia. None of the tumors showed changes at the third position of codon 249 by cleavage analysis of the HaeIII enzyme site at codon 249. A point mutation was identified in one hepatocellular carcinoma at the second position of codon 175 (G to T transversion) by sequencing analysis of the four conserved domains (II to V) in the p53 gene. These data suggest that mutations in the p53 gene are not necessary in aflatoxin B<sub>1</sub>-induced hepatocarcinogenesis in nonhuman primates. The occurrence of mutation in codon 249 of the p53 gene in selective samples of human hepatocellular cancers may indicate involvement of environmental carcinogens other than aflatoxin B<sub>1</sub> or that hepatitis B virus-related hepatitis is a prerequisite for aflatoxin B<sub>1</sub> induction of G to T transversion in codon 249.

Introduction

Dietary exposure to aflatoxin B<sub>1</sub> is an epidemiologically defined risk factor for HCC in southern Africa and China (1-3). Aflatoxin B<sub>1</sub> is also a potent hepatocarcinogen in different species including nonhuman primates (4-6). Recently, a significant number of HCCs in patients from Qidong province in China and from southern Africa, where hepatitis B virus is endemic and dietary exposure to aflatoxin B<sub>1</sub> is high, were found to have a mutation at the third position of codon 249 of the p53 gene (3, 7, 8). It was suggested that this mutation of the p53 gene was caused by aflatoxin B<sub>1</sub> and might contribute to the high incidence of HCC in these areas. The absence of mutation at this hot spot in HCCs in patients from Japan, Taiwan, or Australia support this hypothesis since exposure to aflatoxin B<sub>1</sub> is very low in these areas (3, 9-11). The specificity of this mutational event represents the first clue as to how an environmental toxin may contribute to tumor development (12). It is therefore important to characterize the frequency and patterns of p53 gene mutations in aflatoxin B<sub>1</sub>-induced carcinogenesis. We have examined nine tumors previously induced by aflatoxin B<sub>1</sub> in nonhuman primates (4, 5) for mutations in the p53 gene by restriction enzyme analysis using HaeIII enzyme site at codon 249 and by sequence analysis for mutations within the highly conserved domains II to V which contain four hot spots for mutations in various tumors (13-15). A predicted amino acid sequence of the p53 gene of nonhuman primates is 95% identical to the human protein and that of conserved domain IV including codon 249 is completely identical (16).

Materials and Methods

Tumors in Nonhuman Primates. Nine tumors including four HCCs, two cholangiocarcinomas, a spindle cell carcinoma of a bile duct, a hemangioendothelial sarcoma of a liver, and an osteogenic sarcoma of the tibia were derived from eight nonhuman primates composed of four rhesus (Macaca mulatta) and four cynomolus (Macaca fascicularis) monkeys (Table 1). Aflatoxin B<sub>1</sub> (Calbiochem, Los Angeles, CA; Makor Chemicals, Ltd., Jerusalem, Israel) was administered according to a variety of schedules from 1964 to 1978 (5). Nonhuman primates that died or were sacrificed were carefully necropsied and the tissues were fixed in buffered formalin and embedded in paraffin (5).

DNA Preparation. Extraction of DNA from paraffin embedded tumor tissue was carried out as described previously (17). Briefly, tumor cell areas from two 10-μm sections of each paraffin block were selectively removed based on corresponding hematoxylin and eosin stained sections. The tissues were deparaffinized by xylene, washed with 95% ethanol, and incubated in lysis buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl<sub>2</sub>, 0.32 M sucrose, 1% Triton X-100, 0.5% sodium dodecyl sulfate, and 0.1 mg/ml proteinase K at 70°C for 1 h and 42°C overnight. DNA was extracted from lysis solution with phenol/chloroform, precipitated with ethanol, and dissolved in 100 μl of 10 mM Tris-HCl, pH 8.0.

PCR Amplification. Oligonucleotide primers for PCR amplification were synthesized with an Applied Biosystems DNA synthesizer (model 380B). Identification of sequences are: P1, ACGTGAATTCAACCTGGTGCTCCCTCTCC; P2, TGATCCAGTCACGCTGCTCACC; P3, GGAATTCGGTACGTTACCCATTTCA; P4, ACGTTGGAATTCAACAGGAACGACAGGC; P5, ACGTTGAATCTTACTGCCCCTCGCTTT; P6, ACGTTGAATCTGCGGACCAGGCCTCCCCCTTT. P1, P2, P3, P4, P5, and P6 were derived from intron 4, intron 5, exon 7, intron 7, intron 7, and exon 8, respectively, of p53 gene sequence in nonhuman primates (16). Three sets of primers, P1 and P2, P3 and P4, and P5 and P6, were used for PCR amplification for exons 5, 7, and 8, respectively. PCR amplifications were performed in 100-μl volumes with 20 μl of the DNA solutions consisting of 40 cycles of 95°C (1 min), 55°C (1 min), and 70°C (2 min). PCR reactions contained MgCl<sub>2</sub> at a final concentration of 2 mM (18). Ten μl of PCR products for exon 7 were digested with restriction enzyme HaeIII (New England Biolabs, Inc.) at 37°C for 3 h and fractionated by 3% agarose gel electrophoresis to examine for mutation at codon 249 (8).

Sequencing. The six primers were designed to incorporate extra nucleotides comprising EcoRI or EcoRI and BamHI sites at their 5' ends to facilitate cloning. The PCR products were digested with EcoRI or EcoRI and BamHI, fractionated by 3% low melting agarose gel electrophoresis, and ligated to EcoRI or EcoRI and BamHI digested pGEM vectors (Promega). At least six individual clones were sequenced for each sample by the dyeoxy chain termination method (19) and a total of 180 individual clones were examined for mutations of the p53 gene. To confirm a mutation, subclones obtained from two individual amplifications were sequenced.
Table 1  Mutation of the p53 gene in tumors induced by aflatoxin B1 in nonhuman primates

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Histology</th>
<th>Metastasis*</th>
<th>Monkey*</th>
<th>Species†</th>
<th>Mutation 249* (Codon) others</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hepatocellular carcinoma$^*$</td>
<td>–</td>
<td>692I</td>
<td>Rh</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>Hepatocellular carcinoma$^*$</td>
<td>+</td>
<td>692I</td>
<td>Rh</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>Hepatocellular carcinoma</td>
<td>–</td>
<td>497F</td>
<td>Cy no</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>Hepatocellular carcinoma</td>
<td>–</td>
<td>454F</td>
<td>Rh</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>Cholangiocarcinoma</td>
<td>+</td>
<td>500F</td>
<td>Rh</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>Cholangiocarcinoma</td>
<td>+</td>
<td>473F</td>
<td>Rh</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>Spindle cell carcinoma</td>
<td>–</td>
<td>518G</td>
<td>Cy no</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>Hemangioblastoma</td>
<td>+</td>
<td>498F</td>
<td>Cy no</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>Osteogenic sarcoma</td>
<td>+</td>
<td>508F</td>
<td>Cy no</td>
<td>–</td>
</tr>
</tbody>
</table>

* Indicates metastases to distant organs at time of autopsy.
† Identification of monkeys corresponding to a previous paper of Sieber et al. (5).

* Tumors 1 and 2 are from the same animal. Tumor 1 was from a liver biopsy taken 5 months prior to sacrifice of monkey, whereas tumor 2 was from liver tumor taken at autopsy.

Results and Discussion

Nine tumors derived from eight nonhuman primates treated with aflatoxin B1 were analyzed for mutations in the p53 gene, particularly at the third position of codon 249 (7, 8). PCR products for exon 7 were amplified from DNAs extracted from paraffin sections using primers P3 and P4 and were digested with the restriction enzyme HaeIII. Wild-type p53 alleles are cleaved by HaeIII at codon 249, giving three products of 74, 66, and 41 base pairs. A mutation at the second or third position of codon 249 would result in loss of the HaeIII cleavage site and yield two products of 140 and 41 base pairs. In contrast to human HCCs from Qidong and southern Africa (3, 7, 8), all nine nonhuman primate tumor samples were cleaved by HaeIII at codon 249 of the p53 gene (Fig. 1). To test for mutations at different positions within the p53 gene, exons 5, 7, and 8, which include the highly conserved domains II to V that contain four mutation hot spots (13–15), were amplified from the nine tumors. At least six individual clones for each PCR product were sequenced. A sequence polymorphism was observed at the third position of codon 186, a substitution of T to C, resulting in no amino acid change (Fig. 2). Analysis of the polymorphism revealed no allele loss in eight informative tumors. Only one HCC showed a point mutation at the second position of codon 175, a substitution of G to T, resulting in an amino acid change from arginine to leucine (Fig. 2). The mutation was confirmed by sequence analysis of subclones obtained from two individual amplifications. Although the substitution of G to T at codon 175 might be caused by the preferential binding of aflatoxin B1 to G residues (20), the frequency of mutations in the p53 gene in the tumors was very low (Table 1). These data suggest that, unlike the proposed involvement in human HCCs (3, 7, 8), aflatoxin B1 infrequently induces mutations in the p53 gene in nonhuman primates. Consequently mutations in the p53 gene are not necessary in aflatoxin B1 induced carcinogenesis in nonhuman primates. As to the suggestion that aflatoxin B1 is responsible for the G to T mutation at codon 249 of the p53 gene in human HCCs from Qidong and southern Africa (7, 8), we would like to suggest two possible explanations. One is that aflatoxin B1 may indeed cause the mutation at codon 249 in the p53 gene in nonhuman primates. Since G to T mutation in codon 249 has only been identified in HBV-related human

![Figure 1](https://example.com/fig1.png)  
**Fig. 1.** The digestion profile of amplified fragments for a mutation at codon 249 in the p53 gene. DNA fragments of 181 base pairs (bp) amplified by PCR using P3 and P4 primers were digested with HaeIII restriction enzyme. Wild-type p53 alleles resulted in cleavage by HaeIII at codon 249, giving three products of 74, 66, and 41 base pairs. A mutation at codon 249, which would result in loss of the HaeIII site giving two products of 140 and 41 base pairs, was not observed. Lane C, a control monkey fragment before the HaeIII digestion; Lanes 1 to 9, HaeIII digested fragments from Tumors 1 to 9, respectively. Electrophoresis was performed using 3% agarose gels and DNA was visualized using ethidium bromide.

![Figure 2](https://example.com/fig2.png)  
**Fig. 2.** Identification of a polymorphism and a point mutation of exon 5 in the p53 gene in nonhuman primates. Shown is representative sequence data obtained from a HCC (Tumor 2) as described in the text. The sequence data illustrate the area surrounding and including codon 186 and 175. Panel 1, C-type polymorphism at codon 186 (GAC) and a wild-type sequence at codon 175 (CGC); Panel 2, T-type polymorphism at codon 186 (GAT) and a point mutation at codon 175 (CTC).
HCC, it is possible that both aflatoxin B, exposure and HBV-induced chronic active hepatitis are necessary for induction of the mutation (3, 7). The other explanation is that environmental carcinogens other than and coincident with aflatoxin B, are responsible for the mutation at codon 249 in the p53 gene in human HCCs.

Acknowledgments

The authors acknowledge the assistance of Dr. Unnur Thorgeirsson in making the paraffin blocks available and confirmation of the histopathology and the expertise of Dr. Richard H. Adamson and colleagues in induction of the tumor by aflatoxin B, in nonhuman primates. We also thank Dr. C. C. Harris for many valuable discussions and suggestions during the course of this work.

References

Low Frequency of \( p53 \) Gene Mutation in Tumors Induced by Aflatoxin B\(_1\) in Nonhuman Primates


**Updated version**

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/52/4/1044

**E-mail alerts**

Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.